Immunotherapy for brain cancer
Where the impossible becomes possible
ERC develops Gliovac, an advanced cell-based immunotherapy invented by Prof. Apostolos Stathopoulos for patients with high-grade gliomas, including glioblastoma.
FDA Fast Track DesignationGranted July 2022 for sitoiganap in recurrent glioblastoma
Patients & families
What to expect from Gliovac, the early access program, and how treatment is organised.
Learn more →Doctors
The rationale, mechanism of action and results, and how to donate tumour tissue.
Learn more →Investors
ERC’s vision and strategy, letters to shareholders, and financial statements.
Learn more →Our approach
A new treatment for brain cancer
ERC has developed a unique advanced cancer cell based immunotherapy invented by Pr. Apostolos Stathopoulos for the treatment of patients suffering from brain cancers. This therapeutic vaccine known as GLIOVAC/ERC1671/SITOIGANAP particularly targets high grade gliomas.
ERC seeks to eliminate cancer cells completely, leading to a cure through its unique cell-based immunotherapy approach that treats patients suffering from glioma or glioblastoma by directly stimulating the patient’s immune system with whole cancer cells and cell extracts. ERC has developed a unique, patented process using whole cells and lysates of autologous (patient’s own tumour) and allogeneic tumour cells (from other individuals).
Read about GliovacERC seeks to eliminate cancer cells completely, leading to a cure through its unique cell-based immunotherapy approach that treats patients suffering from glioma or glioblastoma by directly stimulating the patient’s immune system with whole cancer cells and cell extracts. ERC has developed a unique, patented process using whole cells and lysates of autologous (patient’s own tumour) and allogeneic tumour cells (from other individuals).
Scientific innovation
Gliovac · ERC1671 · sitoiganap
Our unique vaccine involves immunisation with glioma derived cells and cell extracts from three or more individuals (allogeneic) as well as cells derived from the patient’s own tumour (autologous). This unique allogeneic/autologous vaccine triggers a powerful rejection response to the allogeneic antigens as well as the patient’s own tumour cells.
Using the basis of Immunotherapy and its design to exploit the natural abilities of our protective immune system, our product entices our own bodies to produce its own killer cells .
Immunotherapy solutions increase life expectancy, but also may improve quality of life for patients with most of the unpleasant, and often harmful, side effects of standard treatments being eliminated.
Using the basis of Immunotherapy and its design to exploit the natural abilities of our protective immune system, our product entices our own bodies to produce its own killer cells .
Immunotherapy solutions increase life expectancy, but also may improve quality of life for patients with most of the unpleasant, and often harmful, side effects of standard treatments being eliminated.
3+
donor tumour cell lines combined with the patient’s own tumour cells
2022
FDA Fast Track Designation for recurrent glioblastoma
Phase II
clinical data published in patients with recurrent glioblastoma
